Technical Assessment on Proteonano™: A Robust Platform for Deep Plasma Proteomics Study
English
Version
Abstract
Complete profiling of human plasma proteome is an immerse source for disease biomarker discovery. Cutting-edge mass spectrometers, like ThermoFisher's Orbitrap Astral, have promised unprecedented insights into the exploration of multiple protein biomarkers from human plasma samples. However, large-scale, deep profiling of the human plasma proteome, especially low-abundant proteins (LAPs, <10 ng mL-1), in a robust and fast way remains challenging. This is largely due to the lack of standardized and automated workflows including LAPs enrichment, reduction, and enzymatic digestion procedures. Until now, these complex procedures have not been incorporated into a streamlined workflow to achieve reproducibility, high-throughput, and deep proteome coverage.
Here we report the Proteonano™️ Ultraplex Proteomics Platform for large cohort plasma proteomics studies with robustness and high throughput by standardizing workflow by incorporating the Proteonano™️ platform and high-resolution mass spectrometers, including Orbitrap Exploris™️ 480, Orbitrap Astral™️, and timsTOF Pro 2. This pipeline demonstrates excellent stability and reproducibility, with tunable balance between detection depth and throughput. We further demonstrate the utility of this platform for biomarker discovery in an Alzheimer disease related cohort. This harmonized platform enables robust, fast and large-cohort plasma proteomics studies to meet the need to discovering new biomarkers.
Proteonano™️: a robust platform for deep plasma proteomics study

Figure 4. Proteomic detection depth of the Proteonano™️ Ultraplex Platform. (A) The same pooled healthy donor plasma sample was processed by either the neat plasma processing pipeline or the Proteonano™️ platform. LC-MS/MS was performed by using a Orbitrap Astral instrument. (B) Comparison of proteomic detection depth using Venn diagram. Overlap of protein groups identified by both sample processing methods and plasma proteins reported by HPPP was determined. (C) Intensity distribution of proteins groups detected. (D) Distribution of HPPP reported plasma protein concentration of identified protein groups. (E) and (F) Changes in intensity and relative abundance of the ten most abundant protein groups identified in the sample processed by neat plasma pipeline. (G) Relative abundance of ten mos